Soligenix, Inc. – Rising to the Challenges of Rare Disease Treatment, has been profiled in the February 2017 edition of Forbes Custom. In this profile, Dr. Christopher J. Schaber, President and CEO, discusses the Company’s pipeline and potential.

Read the Publication

Forbes Custom – Rising to the Challenges of Rare Disease Treatment
Go Back